- Palabras clave > anti-tuberculosis medicines
- Palabras clave > clinical guidelines
- Palabras clave > Drug-resistant tuberculosis (DR-TB)
- Palabras clave > HIV-TB
- Palabras clave > Multidrug-resistant Tuberculosis (MDR-TB)
- Palabras clave > national treatment guidelines
- Palabras clave > Standard Treatment Guidelines
- Palabras clave > TB treatment policies
- Palabras clave > TB/HIV (HIV-related TB)
- Palabras clave > treatment guidelines
(2010; 35 pages)
The strong association of HIV/AIDS and tuberculosis (TB) in Zimbabwe calls for new efforts to address the convergence of the dual epidemics in a collaborative fashion. Its primary aim is to promote the use of standard international evidence based best management practices for TB and HIV co-infection care in Zimbabwe.
This document is not intended to serve as a comprehensive clinical guideline: however, general recommendations related to diagnosis, treatment and overall care have been included to promote adherence to standards and best practices. The guidelines are based on the most recently compiled, evidence-based information available at time of writing. In particular, this document draws heavily from the most recent editions (2009) of the World Health Organization (WHO) TB Treatment Guidelines (4th ed.), and the International Standards for TB Care (ISTC) (2nd ed.). These international standards represent an ideal to be attained, while the guidelines herein attempt to describe current best practices for Zimbabwe. It is the intention of the Ministry of Health and Child Welfare (MOHCW) that these guidelines serve to sensitize care providers to best practices for TB and TB/HIV control through in-service training programs. Educators and trainers in health institutions may also find the guidelines useful in developing teaching materials for pre-service education and training.
Although multidrug resistant TB (MDR-TB) is an escalating problem in southern Africa and a serious threat to TB control, relatively little space in this document is devoted to MDR-TB. Specific national guidelines are to be developed based on national progress in establishing drug susceptibility testing (DST) within the context of comprehensive plans for laboratory strengthening.